Phase I trial of pomalidomide given for patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 755-761

  Cooney, Matthew M ^a   Nock, Charles ^a   Bokar, Joseph ^a   Krishnamurthi, Smitha ^a   Gibbons, Joseph ^a   Rodal, Mary Beth ^a   Ness, Anne ^a   Remick, Scot C ^b   Dreicer, Robert ^c   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Immune modulating agents; Phase I; Pomalidomide

Indexed keywords

POMALIDOMIDE;

ADRENAL CANCER; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLON CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RECOMMENDED DRUG DOSE; RIGOR; SARCOMA; SOLID TUMOR; THROMBOSIS; THYROID CANCER; URTICARIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871218383     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1919-6     Document Type: Article

References (14)

1. D'Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide in an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
2. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276(25):22382-22387
3. Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T (2005) Thalidomide inhibits tumor necrosis factor-Alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 90(5):3017-3021
4. Majumdar S, Lamothe B, Aggarwal BB (2002) Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168(6):2644-2651
5. Sampaio EP, Sarno EN, Galilly R et al (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703
6. Payvandi F, Wu L, Haley M et al (2004) Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-Alpha, IL-1 beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230(2):81-88
7. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG (2004) Phase I study of an immunodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269-3276
8. Zhu D, Corral G, Fleming YW, Stein B (2008) Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57(12):1849-1869
9. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
10. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008-5014 (Epub 2009 Aug 31)
11. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A (2011) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25(2):301-304 (Epub 2010 Nov 5)
12. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27(27):4563-4569 (Epub 2009 Aug 3)
13. Infante JR, Jones SF, Bendell JC, Spigel DR, Yardley DA, Weekes CD, Messersmith WA, Hainsworth JD, Burris HA 3rd (2011) A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. Eur J Cancer 47(2):199-205 (Epub 2010 Nov 2)
14. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107(8):3098-3105